Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21

Lübbert, Michael;Wijermans, Pierre W;Kicinski, Michal;Chantepie, Sylvain;Van der Velden, Walter J F M;Noppeney, Richard;Griškevičius, Laimonas;Neubauer, Andreas;Crysandt, Martina;Vrhovac, Radovan;Luppi, Mario;Fuhrmann, Stephan;Audisio, Ernesta;Candoni, Anna;Legrand, Olivier;Foà, Robin;Gaidano, Gianluca;van Lammeren-Venema, Danielle;Posthuma, Eduardus F M;Hoogendoorn, Mels;Giraut, Anne;Antunes, Stephanie;Stevens-Kroef, Marian;Jansen, Joop H;de Graaf, Aniek O;Efficace, Fabio;Ammatuna, Emanuele;Levesque, Quentin;Wäsch, Ralph;Becker, Heiko;Blijlevens, Nicole;Dührsen, Ulrich;Baron, Frédéric;Suciu, Stefan;Venditti, Adriano;Huls, Gerwin

2026-01-01